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Background: Professional societies recommend shared decision making (SDM) for prostate cancer screening,
however, most efforts have promoted informed rather than shared decision making. The objective of this study is
to 1) examine the effects of a prostate cancer screening intervention to promote SDM and 2) determine whether
framing prostate information in the context of other clearly beneficial men’s health services affects decisions.
Methods: We conducted two separate randomized controlled trials of the same prostate cancer intervention
(with or without additional information on more clearly beneficial men’s health services). For each trial, we enrolled
a convenience sample of 2 internal medicine practices, and their interested physicians and male patients with no
prior history of prostate cancer (for a total of 4 practices, 28 physicians, and 128 men across trials). Within each
practice site, we randomized men to either 1) a video-based decision aid and researcher-led coaching session or
2) a highway safety video. Physicians at each site received a 1-hour educational session on prostate cancer and
SDM. To assess intervention effects, we measured key components of SDM, intent to be screened, and actual
screening. After finding that results did not vary by trial, we combined data across sites, adjusting for the random
effects of both practice and physician.
Results: Compared to an attention control, our prostate cancer screening intervention increased men’s perceptions that
screening is a decision (absolute difference +41%; 95% CI 25 to 57%) and men’s knowledge about prostate cancer
screening (absolute difference +34%; 95% CI 19% to 50%), but had no effect on men’s self-reported participation in
shared decisions or their participation at their preferred level. Overall, the intervention decreased screening intent
(absolute difference −34%; 95% CI −50% to −18%) and actual screening rates (absolute difference −22%; 95% CI −38
to −7%) with no difference in effect by frame.
Conclusions: SDM interventions can increase men’s knowledge, alter their perceptions of prostate cancer screening, and
reduce actual screening. However, they may not guarantee an increase in shared decisions.
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Prostate cancer screening is common despite uncertain
evidence that screening is beneficial [1,2] and mount-
ing evidence that screening may produce net harm [3].
According to national survey data [4], 75% of men age
50 and older in the US have been screened at some
time during their lifetime. This is a striking fact, espe-
cially because only 63% of men in the United States
have had colon cancer screening [4] and less than
two-thirds of men have had screening and treatment
for common cardiovascular risk factors [5-7], screening
procedures which are known to save lives [8-11].
These high rates of prostate cancer screening in the
face of current evidence have raised questions about
how men understand and value prostate cancer screen-
ing compared to other common screening services for
men. In the face of changing professional recommen-
dations [3,12] they have also prompted a call for provi-
ders to use shared decision-making (SDM) [13] to
assist men in deciding whether or not to undergo
prostate cancer screening.
SDM is a process in which patients are involved as ac-
tive partners in clinical decisions. It has been conceptua-
lized in several different ways [14-16], but usually
involves a process in which an individual learns about
the seriousness of the illness; the benefits, harms, alter-
natives, and uncertainty of preventive or treatment
options; weighs his or her values; and participates in the
decision making process with the clinician in a shared
role. The central feature of SDM is participation in the
decision making process with the clinician (at least
enough to abdicate a shared role if this is what they
wish). This shared participation is what distinguishes
SDM from informed decision making. It also is, theoret-
ically, what allows doctors to clarify men’s understanding
of key facts and relevant values, highlight the unique cir-
cumstances that might alter the decision for any individ-
ual, and add a considered perspective on the decision.
Although many have advocated SDM, most recent
efforts to improve decision making about prostate can-
cer screening have focused on the development of deci-
sion aids and the promotion of informed decisions, with
resultant improvements in knowledge and decision con-
fidence and reductions in intent for screening and actual
screening rates [17]. Few decision aids or other efforts
[18-21] have provided the explicit skill building in
patient-provider communication that might be expected
to promote SDM for prostate cancer screening. Add-
itionally, none that we are aware of have directed such
skill building to both patients and providers to optimize
the likelihood of a shared decision. In this manuscript,
we explore the effects of an intervention to promote
SDM for prostate cancer screening (including a video-
based decision aid and researcher led coaching sessionfor patients) that is supported by a 1-hour educational
session for providers on outcomes including key compo-
nents of SDM, intent for prostate cancer screening, and
actual screening rates. We also secondarily explore the
effects of framing prostate cancer screening in the con-
text of other more clearly beneficial men’s health screen-
ing services.
Methods
Study overview
Between March 2005 and April 2006, we conducted two
randomized controlled trials of the same prostate cancer
screening intervention, alone or with additional informa-
tion on two more clearly beneficial men’s health screening
services (cardiovascular disease screening and colon cancer
screening). We conducted each trial in a convenience sam-
ple from two practices (one academic and one community
practice) within a single city (Chapel Hill, NC for the pros-
tate only intervention and Greensboro, NC for the men’s
health intervention). In both trials, we used the same edu-
cational video on highway safety (“Reducing Your Risk in a
Crash” available at http://www.iihs.org/videos/default.html)
as an attention control and employed identical implemen-
tation and measurement strategies to allow combining of
data if no differences were noted in the patient outcomes
of the two trials. In this manuscript we present the com-
bined data from both trials. Our statistical considerations
for combining the data are detailed in the methods below;
results for the individual trials are presented separately in
Additional file 1.
Study sample and recruitment strategy
We invited all physicians from participating practices to at-
tend a 1-hour educational session about prostate cancer
screening and shared decision-making, provide informed
consent, and join our study. Educational sessions were
offered up to three times at each practice site with individ-
ual sessions offered to physicians who expressed interest,
but were unable to attend these sessions.
Within each practice, we then recruited a convenience
sample of men by identifying age eligible men from
weekly schedules of physicians agreeing to participate.
We contacted them via telephone to determine their eli-
gibility. Men were eligible if they were aged 40–80 years
old, had no prior history of prostate cancer, had been
seen in the practice for at least one year, and if their
physician had agreed to participate in the study. They
were excluded if they were presenting for an acute med-
ical visit or if they had evidence of a serious medical ill-
ness (e.g. intensive care hospitalization within the last 6
months, more than 2 hospitalizations in the last 6
months) because they and their physician would be un-
likely to address preventive health issues. We invited eli-
gible men to present for their regularly scheduled
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enroll in the study, and complete study materials.
Intervention structure and content
Our intervention consisted of 2 components designed by
investigators (see Table 1): 1) a video-based decision aid
for patients and 2) a coaching session for patients. The
prostate specific content for our interventions was
derived from a published systematic evidence review on
prostate cancer screening [22]. In the men’s health ver-
sion, this information was framed in the context of in-
formation about the prevalence of cardiovascular disease
and colon cancer, the certain benefit of screening for
these diseases, and the options and attributes of com-
mon screening tests and treatments for these diseases;
see Part A of Additional file 2. Messages were pre-tested
in three rounds of formative research (e.g. focus groups
and cognitive and usability testing) in our target popula-
tion [21] and then incorporated into our intervention.
Video-based decision aid for patients
Our 12-minute video-based decision aid for patients was
designed with three main objectives: 1) to provide the
core information men would need to make an informed
decision about prostate cancer screening, 2) to model the
process of deciding whether or not to be screened, and
3) to help men begin to clarify their values and make a
decision. The video showed four men engaged in an im-
promptu discussion about prostate cancer screening with
their doctor. The discussion occurred after appointment
hours in the clinic waiting room and allowed the doctor
and men to exchange key information and reason to-
gether about the implications of each new piece of infor-
mation provided. It ended with the doctor encouraging
men to consider the facts and decide what they want. To
help facilitate decision making and illustrate the individ-
ual nature of the decision, the doctor encouraged the
men to consider the example of two men (Joe and Frank)
who make opposite decisions using the same facts. To
film the video, we employed an award winning video
company: Insightment Video. Additionally, because mes-
sages were nuanced, we employed actors to deliver the
script. Core video content is shown in Table 1.
Counselor delivered coaching tool for patients
Our 8-minute coaching tool was modeled after an ef-
fective coaching tool by Kennedy and colleagues [23]
and employed scripted materials delivered by a trained
health counselor. It had three main objectives: 1) to
answer men’s additional questions about prostate can-
cer screening, 2) to help men further clarify their
values for prostate cancer screening, and 3) to prepare
men to discuss prostate cancer screening with their
doctor (see Additional file 2).We addressed additional questions we anticipated men
might have through a supplemental brochure. The bro-
chure reinforced and expanded on content presented in
the video and included the following topics: the location
of the prostate, the characteristics of prostate cancer and
the PSA test, the risk factors for prostate cancer (age,
family history, race), and treatment options for prostate
cancer (radiation and surgery), including their side
effects. Like other materials, brochures were framed to
discuss prostate screening alone or broader issues of
men’s health. Copies of relevant brochures were given to
each man to take home.
We helped men clarify their values for prostate cancer
screening using a process in which men rated and then
ranked the relative importance of several factors in their
decision making. The decision factors included: 1) the
chances of dying from prostate cancer, 2) the need to
know whether or not one has cancer, 3) the certainty of
the diagnosis provided by the PSA test, 4) the certainty
of benefit from screening and treatment, and 5) worry
over treatment side effects. We first asked men to read a
series of two opposing statements about each decision
factor and choose which statement best represented
their own feeling about that factor. For instance, for the
factor “need to know”, men chose between the following
two statements: 1) I don’t like the idea of having prostate
cancer and not knowing it even though more prostate
cancers are harmless than dangerous, or 2) I’m ok with
not knowing I have prostate cancer because more pros-
tate cancers are harmless than dangerous. We then
asked men to rank which three of their five chosen state-
ments most affected their decision making and state
whether or not they intended to be screened or were still
unsure and needed to consider it further. To facilitate
the process of rating and ranking, all statements were
written on laminated cards that could be rearranged for
consideration.
To help men prepare for discussions about prostate can-
cer screening with their doctor, we first asked men to con-
sider how involved they’d like to be in decision making
about prostate cancer screening. We then delivered
scripted counseling on how to address barriers to commu-
nication. Men endorsed barriers from the following list:
1) discomfort asking the doctor questions; 2) fear of upset-
ting the doctor by expressing opinions; 3) difficulty inter-
rupting the doctor; 4) concern that it is not one’s place to
disagree with the doctor; 5) worries of taking up too much
of the doctor’s time; 6) difficulty understanding doctors
who use medical jargon; and 7) embarrassment over not
knowing things and having to ask the doctor questions.
They then received counseling on as many barriers as they
endorsed. Following counseling, men received a “list pad”
which summarized key messages and encourage men to
write down questions to ask their doctor.
Table 1 The intervention structure and content
Intervention component Purpose Content
Video for Patients 1) To describe key messages about prostate
cancer screening
1) Key messages:
• There are two kinds of prostate cancer—harmless
and dangerous
• A problem with the PSA test is that it leads some
men with a harmless prostate cancer to get treatment
that they do not need.
• About half of all men who get treatment for prostate
cancer will have permanent side effects
• Men should decide whether the PSA test is right for
them and talk with their doctor.
2) To model the process of learning and
deciding about prostate cancer screening
2) Modeling:
• 4 men engage in an after-hours discussion with
their physician
• Each man participates in questioning and reasoning
about screening
3) To facilitate values clarification via a
process of social matching with two men
making opposite decisions using the
same facts
Values Clarification:
• Joe decides to get the PSA test after considering
the facts
• Frank decides NOT to get the PSA test after
considering the facts
Coaching Session for Patients 1) To answer men’s questions about prostate
cancer screening by providing a supplemental
educational brochure
1) Key facts:
• Location of the prostate
• Characteristics of the PSA test
• Characteristics of prostate cancer
• Risk factors for prostate cancer
• Treatment options and their side effects
2) To help men clarify their values for screening
by ranking and rating decisional attributes
2) Decisional Attributes:
• Magnitude of the problem (e.g. prostate cancer)
• Benefit in knowing one has prostate cancer
• The (un)certainty of the PSA test
• The (un)certainty of treatment outcomes
• Worry about treatment side effects
3) To help men prepare for a discussion with
their doctor by delivering tailored messages
about discussion barriers and by providing a pad
on which to write their screening decision and
any questions for their doctor
2) Barriers to Discussion:
• Discomfort asking questions
• Fear of expressing opinions
• Difficulty interrupting the doctor
• Difficulty disagreeing with the doctor
• Worry about taking too much of the doctor’s time
• Difficulty understanding medical jargon
• Embarrassment asking questions
Education Session for Providers 1) To review the evidence for prostate
cancer screening
1) Evidence:
• Natural History of prostate cancer
• Lack of clear benefit of prostate cancer screening
• Certain harms of screening and early treatment
2) To highlight the value of shared decision
making for prostate cancer screening
2) Value of Shared Decision Making:
• Ethical obligation to consider patient preferences in
the face of uncertain outcomes
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randomization
The patient intervention and accompanying surveys
were delivered to participants prior to regularly
scheduled medical appointments in a private room
in each practice. After providing informed con-
sent and completing a baseline survey, eligible men
were randomized within practices to receive one of
the SDM interventions or a highway safety control
video. Randomization used computer-generated ran-
dom numbers that were sealed in opaque envelopes.
Men in the intervention groups watched one of our
informational videos and then were guided through a
coaching session by a trained research assistant. At
the end of the coaching session, men were given a
summary sheet of their opinions on prostate cancer
screening to share with their physician. Men in the
highway safety group viewed the highway safety
video, but received no accompanying coaching ses-
sion. After completion of these interventions, all men
completed a 2nd questionnaire to assess immediate
changes in their knowledge and attitudes about pros-
tate cancer screening. Men then proceeded to their
visit with their physician (who was notified only
about patients’ participation, but not group assign-
ment) and, on completion of their visit, filled out a
final questionnaire about the content of their visit
with their physician.
Physicians in our study were also asked to complete a
baseline questionnaire so that we could capture their
demographics, knowledge, and attitudes about screening.
Measurement
We measured the main effect of our SDM interventions
by examining three key components of shared decision
making. We then, secondarily, measured men’s decision
for screening following their doctor’s visit, and their ac-
tual screening rates at 9 month follow-up.
Measuring the key components of shared decision-making
To assess the effects of our intervention, we measured
the following three outcomes: 1) perception that prostate
screening requires a personal decision, 2) knowledge
about prostate cancer and prostate cancer screening,
and 3) participation in the decision-making, including
both shared participation and participation at their pre-
ferred level [16].
Perception that prostate cancer screening requires a
decision To measure perception that prostate cancer
screening requires a decision, we assessed men’s agreement
with the following statement: “it is okay to decide not to
have a PSA test after learning the facts.” This question is
one of three questions in the “PSA is a Decision” score(alpha 0.76), is highly correlated with overall scale results
[24], and was been shown to be sensitive to intervention
effects in community study of PSA decision making that
was conducted by our research team. Responses were
scored on a 5-point Likert scale (strongly agree to strongly
disagree) and categories were collapsed to create a dichot-
omous variable showing men’s agreement (strongly agree
or agree) with this statement.
Knowledge about prostate cancer screening To meas-
ure knowledge about prostate cancer screening, we
designated four key knowledge questions, which cap-
tured the core messages in our intervention and repre-
sented knowledge we felt was essential to making a good
decision about prostate cancer screening. These ques-
tions highlighted the benign natural history of most
prostate cancers and the high likelihood of side effects
with treatments delivered for prostate cancer detected
by PSA screening: 1) “Some men can live long lives with
prostate cancer,” 2) “most men diagnosed with prostate
cancer die of something else,” 3) “problems with sexual
function is a common side effect of prostate cancer treat-
ments,” and 4) “problems with urination is a common side
effect of prostate cancer treatments.” These true-false
questions were adapted from questions used in other trials
of prostate screening [25]. If men agreed with all of these
statements, they were considered to have the key know-
ledge necessary for an informed decision.
Participation in decision-making To measure men’s
preferred participation in decision-making, we adapted
a widely employed measure for use in a survey format
[26]. Our 5-point Likert question asked men “how
much would you like to be involved in the decision
about whether or not to get the PSA test,” with
responses on a continuum between making the final de-
cision themselves or having the doctor make the deci-
sion himself. For analysis, we collapsed answers into
three categories (patient decision (I decide); shared de-
cision (I decide after considering the doctor’s opinion +
doctor and I decide together + doctor decides after
considering my opinion); and doctor’s decision (doctor
decides). We also specifically assessed who reported
shared rather than independent (either doctor or patient)
decision making.
To measure men’s actual participation, we asked a
similar question: “how much were you involved in the
decision about whether or not to get a PSA test today?”
Responses were provided on the same Likert scale with
one additional response category: we talked about the
PSA test, but didn’t make a final decision. We collapsed
this response with shared decisions, consistent with sev-
eral shared decision making models calling for patients
and physicians to make or delay decisions.
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and compared men’s preferred participation after the
intervention with their stated participation during their
visit to determine whether men participated in decision-
making at their desired level.
Measuring intent for screening
We measured men’s intent for screening before and after
the intervention using a single item question: “In the
next 12 months, do you plan to get a PSA test?”
Measuring actual screening rates
We determined actual prostate cancer screening rates in
two ways. First, we asked men immediately following
their visit with their clinician “Did you get a PSA today?”
Second, we reviewed men’s medical records approxi-
mately nine months following their study visit to deter-
mine whether they’d followed through with their
original decision about prostate cancer screening.
Measuring baseline characteristics that might affect
prostate cancer decisions and screening
Because of our small sample size and the possibility that
randomization may have resulted in an unequal distribu-
tion of patient characteristics across groups, we mea-
sured several characteristics of men and physicians that
might affect patients’ decision making and actual screen-
ing rates. Men’s characteristics included self-reported
age, race, education, marital status, usual source of care,
family history of prostate cancer, prior history of PSA
tests, abnormal PSA tests, and prostate biopsies. We also
measured men’s certainty with their plans for prostate
cancer screening using the 3-item uncertainty subscale
from O’Connor’s Decisional Conflict Scale [27]. Physi-
cian’s characteristics included self-reported age, race,
gender, prior history of PSA testing, preferred approach
to prostate cancer screening (e.g. do it, discuss it, or
don’t discuss/don’t do), preference for SDM, and percep-
tions that their patients are involved enough to influence
decisions.
Statistical analysis
To assess the randomization process, we compared the
baseline characteristics of subjects assigned to the SDM
interventions with those assigned to the control group.
Within each of our two randomized trials, we then
examined the effect of our interventions on the key
components of SDM and on men’s decisions and actual
screening rates. Finding no difference in the patient out-
comes between the two individual trials (see Additional
file 1), we then combined data from the two trials for all
subsequent analyses, accounting for the random effects
of practices as is done in meta-analysis.In combined analysis, we examined the effect of the
SDM interventions on the key components of SDM by
comparing differences in the key components of SDM
post-intervention between study arms. To deepen our
understanding of intervention effects, we also examined
changes in the key components of SDM across study
arms (see Additional file 3). We used Pearson’s chi-
square tests (SAS Statistical Software, Cary, NC) to
evaluate whether the interventions significantly affected
men’s decision for screening, and their actual screening
rates. For these unadjusted analyses, we report absolute
differences and confidence intervals between the inter-
vention and control groups to allow interpretation of the
magnitude of clinical effect.
We then used mixed effects logistic regression models
to examine whether the intervention affected outcomes
after adjusting for the random effects of both practices
and physicians and for the baseline differences among
intervention groups. For each model, we adjusted only
for conceptually relevant covariates that were 1) related
to the outcome in bivariate analysis, and 2) changed the
outcome of the model by more than 10% when added in
forward stepwise regression. Because results varied with
adjustment, we report both unadjusted and adjusted
analyses. We calculated relative risks from odds ratios
using standard formulas [28]. When adjusted analyses
involved dichotomous covariates, we present adjusted
relative risks based on clinically relevant covariate
responses (e.g. plans for PSA = probably or definitely
yes; history of PSA =yes)
Sample size calculation
Sample size was primarily driven by budgetary and prac-
tical considerations. We expected the 128 individuals
would provide adequate power for the overall compari-
son of interventions arms for most outcomes of interest.
Results
We recruited 36 physicians to participate in our study
(11% of eligible physicians at the academic practice in
Chapel Hill; 100% of eligible physicians at the commu-
nity practice in Chapel Hill; 100% at the academic prac-
tice in Greensboro; 75% at the community practice in
Greensboro). 28 physicians saw patients enrolled in our
study and are therefore included in our analysis; their
characteristics are shown in Table 2. In general, these
physicians were young, predominantly male, and pre-
ferred a shared approach to decision-making about pros-
tate cancers screening. Most of the included male
physicians had never been screened for prostate cancer.
Our patient recruitment is shown in Figure 1. In total,
we recruited and enrolled 130 patients (70 in the control
group and 58 in the intervention group) and 128 com-
pleted the study. The baseline characteristics of included
Table 2 Physician characteristics (n = 28)
Mean age (range) 36 (27 to 57)
Male Gender 54%
Race
White 64%
African-American 18%
Other 18%
History of PSA Screening *
Ever 33%
Never 67%
Approach to Prostate Cancer Screening
Do it 4%
Discuss it 71%
Don’t discuss/don’t do it 25%
Prefer Shared DM for PCS 79%
Patients Involved Enough to Affect Decision
Almost always 11%
Very often 21%
Often 36%
Seldom 25%
Almost never 7%
*Males Only.
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intervention groups were similar with regard to age,
race, educational status, marital status, and usual source
of care. Participants in the control group, however,
reported more prior screening, more discussions about
prostate cancer screening in the last 12 months, and
more plans for screening in the next 12 months. Partici-
pants in the control group were additionally slightly less
likely to consider prostate cancer screening a decision
and slightly more likely to have key knowledge about
prostate cancer screening.The effect of the intervention on key components of
decision making
In the post intervention period, more men in the inter-
vention group than in the control group agreed that
prostate cancer screening is a decision (see Table 4; ab-
solute difference: 41%, 95% CI 25% to 57%; fully adjusted
RR 2.79, 95% CI 1.96 to 3.47) and had the key know-
ledge necessary to make a good decision (absolute differ-
ence: 34%, 95% CI 19% to 50%; fully adjusted RR 4.28,
95% CI 2.30 to 6.45). Men in the intervention group,
however, were no more likely to participate in shared deci-
sion making (absolute difference post-intervention: -3%,
95% CI −21% to +15%; fully adjusted RR 0.96, 95% CI 0.67
to 1.15) or decision making at their preferred level (abso-
lute difference post-intervention: -5%, 95% CI −24% to+13%; fully adjusted RR 0.92, 95% CI 0.64 to 1.11) than
men in the control group.
The effect of the intervention on intent for screening and
actual screening rates
Immediately after receiving our intervention, 79% of
men in the control group reported plans for PSA screen-
ing in the next 12 months compared with 45% of men in
intervention group (see Table 5; absolute difference:
-34%, 95% CI −50% to −18%; fully adjusted RR 0.18, 95%
CI 0.06 to 0.48). Concordantly, immediately following
their doctor’s visit, fewer men in the intervention group
than the control group reported they had been screened
(unadjusted absolute difference −21%, 95% CI −38% to 4%;
fully adjusted RR 0.42, 95% CI 0.14 to 1.24). Screening
rates by chart review at 9 months showed similar results
(unadjusted absolute difference −22%; 95% CI −38 to −7%;
fully adjusted RR 0.79, 95% CI 0.50 to 0.97) with rates
remaining appreciably lower in both groups than men’s
stated plans for screening.
Discussion
In a combined analysis of two randomized controlled
trials promoting SDM for prostate cancer screening,
the intervention had mixed effects on the key com-
ponents of SDM: it increased men’s perception that
screening is a decision and men’s knowledge about
prostate cancer screening, but had no effect on men’s
preferred or actual participation in shared decisions.
Men who were exposed to the intervention were sig-
nificantly less likely to plan to get screened in the
next 12 months and actually get screened according
to chart review at 9 months.
Our findings suggest the ability of SDM interven-
tions to increase men’s knowledge and alter their in-
tent for prostate cancer screening, but additionally
highlight the complexities of promoting SDM: namely
helping men participate equally with their clinician, or,
at least, participate at a level at which they desire. We
designed our intervention to prepare both men and
doctors for SDM. We encouraged men to consider the
facts, decide what they wanted, and talk with their
doctor and, then, provided advice on overcoming bar-
riers to talking with their doctor. Additionally, we pro-
vided doctors with one session of education on the
rationale and recommendations for SDM. With these
efforts, we increased the proportion of men who per-
ceived prostate cancer screening to be a decision and
had adequate knowledge and decreased intent for
screening. We did not, however, increase the propor-
tion of men who shared a decision with their doctor
or participated at the level they desired. There are four
possible explanations for these findings: men either a)
talked with their doctor and agreed that a primarily
4th site contributes 17 
participants; recruitment 
data missing
Patients contacted about 
participation (n=474)*
104 refused*
220 ineligible*:
97 not long term with PCP
8 wrong age
43 difficulty with ADLs
60 serious medical illness
12 access constraints
37 no show at clinic*
Patients randomized 
(n=130)
Intervention 
Group (n=60) Control Group (n=70)
Completed Study 
(n=70)
Completed Study
(n=58)
Potentially eligible 
patients (n=872)*
114patients agreed to 
participate
2 false inclusions
Figure 1 Recruitment and Enrollment.
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value in equal participation when they had already
received the relevant facts, clarified their values, and
considered what they wanted, c) didn’t (despite our
intervention) know how to engage the doctor for equal
participation when they wanted to, or d) had a doctor
who (despite our educational session) didn’t engage in
shared decisions.
An important question given our results is whether
there is an added benefit of sharing the decision with
a doctor beyond getting the facts and consideringone’s own values. The theoretical benefit of sharing
the decision is that it allows doctors to clarify men’s
understanding of key facts and relevant values, high-
light the unique circumstances that might alter the
decision for any individual, and add a considered
perspective on the decision. Several of these func-
tions may not be necessary when decision aids are
available, particularly if men are known to be health
literate and the decision aid allows for deliberation
on values and preferences. Instead, independent deci-
sion making (with the doctor in a supporting role)
Table 3 Baseline patient characteristics
Control Intervention
(n = 70) (n = 58)
Mean age (range) 58 (41 – 74) 57 (41 – 78)
White race 56% 53%
Education: 70% 65%
At least some college
Marital Status: 59% 64%
Married
Personal Doctor 96% 96%
FH of Prostate Cancer 13% 4%
Discussed PSA with MD in last 12 months 51% 41%
Prior MD recommendation for screening 22% 14%
Previous PSA Screening (ever) 59% 44%
Previous Abnormal PSA 10% 7%
Plan for PSA Screening in next 12 months 80% 69%
Think PSA Screening is a Decision 17% 34%
Have Key Knowledge about PSA Decision* 10% 3%
Preferred Participation in DM:
I decide 16% 25%
Share decision 77% 71%
MD decides 7% 4%
Decisional Conflict, uncertainty score (sd)† 1.9 (0.8) 1.9 (0.8)
*Key knowledge: Agreement with the following four statements: 1) Some
men can live long lives with prostate cancer, 2) most men diagnosed as
prostate cancer die of something else, 3) problems with sexual function is a
common side effect of prostate cancer treatments, and 4) problems with
urination is a common side effect of prostate cancer treatments.
†Decisional Conflict, uncertainty score: Mean agreement on 1–5 scale for
the following 3 questions: 1) The decision is easy for me to make, 2) I am sure
what to do in this decision, 3) It is clear what choice is best for me.
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self-efficacy for following through with a decision
[29]. Whether a shared decision adds benefit over an
informed decision is an empirical question that
should be addressed in future research. An observa-
tional analysis of the outcomes that result when deci-
sions are either shared, made at a level which men
desire and feel comfortable, or made without regard
to men’s preferences, would be helpful in resolving
questions about SDM (especially if the analysis is fo-
cused on outcomes such as value concordance and
adherence to decisions). Additionally, an analysis of
the frequency of decisions in which clinicians’ input
might substantially alter the decision making process
would be helpful.
Future research should also attempt to measure the
relative contribution of each component included in
SDM interventions. We are unclear which compo-
nents of our intervention had the most impact on
decision making and screening outcomes or of theindependent value of our novel coaching tool. Test-
ing the relative effect of various components will aid
construction of new interventions and refinement of
existing ones. Future work might also explore other
intervention components or component content that
might make SDM interventions more effective in
promoting shared decisions. For instance, researchers
might explore alternate messages about how to share
a decision (i.e. men should clearly state their prefer-
ence for decision making; or men should ask their
doctor whether their unique circumstances should alter
the decision making process). Researchers might also ex-
plore stronger interventions for physicians (i.e. to help
them identify patients’ preferences and encourage ques-
tion asking). A few simple changes might refocus men
and their physicians on the value of sharing decisions and
facilitate the process, thereby promoting such decisions.
In considering future directions, researchers should
also consider how to improve on the methods we used.
First, our study sample included a convenience sample
of men, who may have exhibited differences from the
source population from which they were sampled. Fu-
ture work should consider random sampling from the
source population. Second, despite randomization, the
small size of our study resulted in differential distribu-
tion of confounders among study groups. We controlled
for this in multivariate analysis, but recognize the poten-
tial that unmeasured confounders may have affected our
results. Future work should employ larger sample sizes
to ensure the success of randomization. Third, because
we randomized at the patient level, physicians saw
patients in both the intervention and control groups,
creating the possibility for contamination. Future work
with greater resources should consider randomization of
physicians or practices. Fourth, other factors may have
biased our effect size. Providers may have altered their
behavior merely because they knew they were being
watched. Similarly, patients or providers may have
altered their survey responses because based on their
study assignment (or assessment thereof ). Fifth, our
measures of the key components of SDM (including our
measures of knowledge and patient participation)
haven’t been formally validated. Future work should
consider a full assessment of the validity and reliability
of our measures or alternate methods of measuring
knowledge [25] and patient participation [30] to ensure
the validity of conclusions. More extensive knowledge
and participation measures and/or newer measures of
informed and shared decision making might draw differ-
ent conclusions [31-33]. Finally, the generalizability of
our sample may be limited. We enrolled a convenience
sample of men from 4 conveniently located academic
and community practices in two cities in North Carolina.
Approximately 45% of men had engaged in discussions
Table 4 The effect of the intervention on key components of decision making
Control,
% (n)
Intervention,
% (n)
Unadjusted absolute
difference
Unadjusted RR Adjusted RR Adjusted RR Adjusted RR
(n = 70) (n = 58) (95% CI)* (95% CI) (95% CI)† (95% CI) ‡ (95% CI) §
Overall
% of Men Agreeing PSA
is a Decision,
post-intervention:
23% (16) 64% (37) 41% (25 to 57%) 2.79 (1.74 to 4.47) 3.57 (2.33 to 7.69) 2.79 (1.96 to 3.47) —∥
%Men Having Key
Knowledge,
post intervention:
13% (9) 47% (27) 34% (19 to 50%) 3.63 (1.86 to 7.08) 4.55 (2.38 to 33.3) 4.28 (2.30 to 6.45) —∥
Among Men Who Talked with Their Doctor about PSA Testing
Control,
% (n)
Intervention,
% (n)
Absolute Difference Adjusted RR Adjusted RR Adjusted RR
(n = 51) (n = 38) (95% CI)* (95% CI)† (95% CI)‡ (95% CI) §
% of Men Reporting
Shared Decisions,
post-visit:
76% (39/51) 74% (28/38) −3% (−21% to +15%) 0.96 (0.76 to 1.23) 1.01 (0.76 to 1.27) 0.96 (0..67 to 1.15) —∥
% of Men Reporting
Participation at preferred
level, post-visit
76% (39/51) 71% (27/38) −5% (−24% to +13%) 0.92 (0.72 to 1.20) 0.93 (0.74 to 1.23) 0.92 (0.64 to 1.11) —∥
*Pearson Chi-square tests.
† Adjusted for random effects of physician.
‡ Adjusted for random effects of physician and practice.
§Adjusted for random effects of physician and practice + family history of prostate cancer, history of PSA testing, receipt of physician recommendation for testing,
current plans for PSA testing, and patient approach to discussing PSA testing at next visit (as applicable after stepwise regression).
∥Not reported because no baseline variables retained in model during modeling process.
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may be a more educated and activated group than most.
Sampling from more diverse practices in diverse locations
would improve the generalizability of data. Further, we
addressed only 1 clinical decision (e.g. prostate cancer
screening). To the extent that preferred and actual involve-
ment in decision making differs across clinical decisions,
the benefits of shared decision making interventions simi-
lar to ours (i.e. including a decision aid, coaching session,
and physician education session) may differ across deci-
sions and should be tested.Table 5 Effect of the intervention on men’s decisions and act
Control,
% (n)
Intervention,
% (n)
Unadjusted Absolute
Difference *
Un
(n = 70) (n = 58) (95% CI)
Intent for Screening
Post Intervention
79% (55) 45% (26) −34% (−50% to −18%) 0.5
Patient reported
screening after
clinical visit
31% (16) 11% (4) −21% (−38% to −4%) 0.4
Actual Screening at
9 months
41% (29) 19% (11) −22% (−38 to −7%) 0.4
* Pearson’s chi-square tests.
†Adjusted for random effects of physician.
‡Adjusted for random effects of physician and practice.
§Adjusted for random effects of physician and practice and for family history of pro
testing, current plans for PSA testing, and patient approach to discussing PSA testin
∥Adjusted only for plans for PSA testing; other covariates dropped out of model.
** Adjusted only for History of PSA test; other other covariates dropped out of modConclusions
Despite limitations, we believe our study makes import-
ant contributions to—and raises critical questions about-
-our understanding of SDM. SDM interventions may
not guarantee increases in shared decisions, but none-
theless change clinical outcomes. More work is needed
to determine the added value of a shared decision (above
and beyond an informed decision), and, if of added
value, how to best promote a shared decision. Parts of
this work were previously presented at the National So-
ciety of General Internal Medicine meeting in May 2006.ual screening rates
adjusted RR Adjusted RR Adjusted RR Adjusted RR
(95% CI) † (95% CI) ‡ (95% CI) §
7 (0.42 to 0.78) 0.46 (0.34 to 0.73) 0.57 (0.35 to 0.81) 0.18 ( 0.06 to 0.48)∥
4 (0.17 to 1.08) 0.27 (0.12 to ∞) 0.43 (0.16 to 0.96) 0.42 (0.14 to 1.24)∥
5 (0.25 to 0.83) 0.43 (0.26 to 1.41) 0.42 (0.20 to 0.81) 0.76 (0.50 to 0.97)**
state cancer, history of PSA testing, receipt of physician recommendation for
g at next visit (as applicable after stepwise regression).
el.
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